Literature DB >> 1695251

Mutagenic analysis of the v-crk oncogene: requirement for SH2 and SH3 domains and correlation between increased cellular phosphotyrosine and transformation.

B J Mayer1, H Hanafusa.   

Abstract

We have constructed a series of mutants with deletion, linker insertion, and point mutations in the v-crk oncogene of avian sarcoma virus CT10. The v-crk gene contains no apparent catalytic domain, but does contain two blocks of homology to putative regulatory domains, termed SH2 and SH3, found in a variety of proteins implicated in signal transduction. Infection with CT10 causes a dramatic increase in the level of tyrosine phosphorylation of several cellular proteins. We found that mutation of either the SH2 or SH3 domain of v-crk reduced or eliminated transforming activity, whereas mutation of regions outside the conserved domains had no effect. Deletion of amino-terminal gag sequences caused a partial loss of transforming activity and a change in subcellular distribution of the crk protein. In all cases, there was an absolute correlation between increased cellular phosphotyrosine and transformation.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1695251      PMCID: PMC249650     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  35 in total

1.  Similarity in membrane proteins.

Authors:  A R Rodaway; M J Sternberg; D L Bentley
Journal:  Nature       Date:  1989-12-07       Impact factor: 49.962

2.  Localization of major potential substrates of p60v-src kinase in the plasma membrane matrix fraction.

Authors:  M Hamaguchi; H Hanafusa
Journal:  Oncogene Res       Date:  1989

3.  Phospholipase C-148: chromosomal location and deletion mapping of functional domains.

Authors:  A Bristol; S M Hall; R W Kriz; M L Stahl; Y S Fan; M G Byers; R L Eddy; T B Shows; J L Knopf
Journal:  Cold Spring Harb Symp Quant Biol       Date:  1988

4.  Molecular cloning of two types of GAP complementary DNA from human placenta.

Authors:  M Trahey; G Wong; R Halenbeck; B Rubinfeld; G A Martin; M Ladner; C M Long; W J Crosier; K Watt; K Koths
Journal:  Science       Date:  1988-12-23       Impact factor: 47.728

5.  Fatty acylation of cellular proteins. Temporal and subcellular differences between palmitate and myristate acylation.

Authors:  E N Olson; G Spizz
Journal:  J Biol Chem       Date:  1986-02-15       Impact factor: 5.157

6.  Changes in protein phosphorylation in Rous sarcoma virus-transformed chicken embryo cells.

Authors:  J A Cooper; T Hunter
Journal:  Mol Cell Biol       Date:  1981-02       Impact factor: 4.272

7.  Homology of a yeast actin-binding protein to signal transduction proteins and myosin-I.

Authors:  D G Drubin; J Mulholland; Z M Zhu; D Botstein
Journal:  Nature       Date:  1990-01-18       Impact factor: 49.962

8.  Association of the v-crk oncogene product with phosphotyrosine-containing proteins and protein kinase activity.

Authors:  B J Mayer; H Hanafusa
Journal:  Proc Natl Acad Sci U S A       Date:  1990-04       Impact factor: 11.205

9.  A newly isolated avian sarcoma virus, ASV-1, carries the crk oncogene.

Authors:  H Tsuchie; C H Chang; M Yoshida; P K Vogt
Journal:  Oncogene       Date:  1989-11       Impact factor: 9.867

10.  A second type of rat phosphoinositide-specific phospholipase C containing a src-related sequence not essential for phosphoinositide-hydrolyzing activity.

Authors:  Y Emori; Y Homma; H Sorimachi; H Kawasaki; O Nakanishi; K Suzuki; T Takenawa
Journal:  J Biol Chem       Date:  1989-12-25       Impact factor: 5.157

View more
  41 in total

1.  v-Crk activates the phosphoinositide 3-kinase/AKT pathway in transformation.

Authors:  T Akagi; T Shishido; K Murata; H Hanafusa
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-20       Impact factor: 11.205

2.  Cytokine regulation of gap junction connectivity: an open-and-shut case or changing partners at the Nexus?

Authors:  C F Brosnan; E Scemes; D C Spray
Journal:  Am J Pathol       Date:  2001-05       Impact factor: 4.307

3.  Biological and biochemical activity of v-Crk chimeras containing the SH2/SH3 regions of phosphatidylinositol-specific phospholipase C-gamma and Src.

Authors:  M Matsuda; C T Reichman; H Hanafusa
Journal:  J Virol       Date:  1992-01       Impact factor: 5.103

4.  Point mutations in the abl SH2 domain coordinately impair phosphotyrosine binding in vitro and transforming activity in vivo.

Authors:  B J Mayer; P K Jackson; R A Van Etten; D Baltimore
Journal:  Mol Cell Biol       Date:  1992-02       Impact factor: 4.272

5.  Multiple SH2-mediated interactions in v-src-transformed cells.

Authors:  C A Koch; M F Moran; D Anderson; X Q Liu; G Mbamalu; T Pawson
Journal:  Mol Cell Biol       Date:  1992-03       Impact factor: 4.272

6.  The noncatalytic src homology region 2 segment of abl tyrosine kinase binds to tyrosine-phosphorylated cellular proteins with high affinity.

Authors:  B J Mayer; P K Jackson; D Baltimore
Journal:  Proc Natl Acad Sci U S A       Date:  1991-01-15       Impact factor: 11.205

7.  Identification and characterization of a high-affinity interaction between v-Crk and tyrosine-phosphorylated paxillin in CT10-transformed fibroblasts.

Authors:  R B Birge; J E Fajardo; C Reichman; S E Shoelson; Z Songyang; L C Cantley; H Hanafusa
Journal:  Mol Cell Biol       Date:  1993-08       Impact factor: 4.272

8.  The WW domain of Yes-associated protein binds a proline-rich ligand that differs from the consensus established for Src homology 3-binding modules.

Authors:  H I Chen; M Sudol
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-15       Impact factor: 11.205

9.  Models of crk adaptor proteins in cancer.

Authors:  Emily S Bell; Morag Park
Journal:  Genes Cancer       Date:  2012-05

10.  The human GRB2 and Drosophila Drk genes can functionally replace the Caenorhabditis elegans cell signaling gene sem-5.

Authors:  M J Stern; L E Marengere; R J Daly; E J Lowenstein; M Kokel; A Batzer; P Olivier; T Pawson; J Schlessinger
Journal:  Mol Biol Cell       Date:  1993-11       Impact factor: 4.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.